On June 22, Hengrui Medicine (01276.HK) declined 3.02% in regular trading, trading at HK$52.95/share, with turnover of HK$66.36 million. The decline came amid a broad sell-off across the Hong Kong-listed pharmaceuticals sector.

The downturn aligns with ongoing macro headwinds identified by JPMorgan in a June 16 report, which noted that Hengrui's stock had fallen approximately 40% from its 52-week high. The bank attributed the weakness primarily to escalating US-China geopolitical tensions and institutional de-risking from H-share healthcare exposure, rather than any deterioration in company fundamentals. JPMorgan upgraded Hengrui to Overweight with a HK$68 target price, citing undervalued earnings trajectory and pipeline expansion.

Within the Pharmaceuticals sector, declines were broad-based. CSPC Pharma fell 3.77%, Hansoh Pharma fell 1.74%, SBP Group fell 4.59%, United Lab fell 3.39%, and Luye Pharma fell 5.05%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)